Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib

Keizman D., Sarid D., Lee J. L., Sella A., Gottfried M., Hammers H., ...More

ONCOLOGIST, vol.21, no.10, pp.1212-1217, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 10
  • Publication Date: 2016
  • Doi Number: 10.1634/theoncologist.2015-0428
  • Journal Name: ONCOLOGIST
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1212-1217
  • Keywords: Metastatic renal cell carcinoma, Chromophobe type, Clear cell type, Outcome, Sunitinib, PROGRESSION-FREE, SURVIVAL, EFFICACY, TRIAL
  • Acibadem Mehmet Ali Aydinlar University Affiliated: No


Background. Sunitinib is a standard treatment for metastatic clear cell renal cell carcinoma (mccRCC). Data on its activity in the rare variant of metastatic chromophobe renal cell carcinoma (mchRCC), are limited. We aimed to analyze the activity of sunitinib in a relatively large and homogenous international cohort of mchRCC patients in terms of outcome and comparison with mccRCC.